



## Press Release

### Lotus Surgicals Private Limited (LSPL)

**December 16, 2022**

#### Ratings:

Instrument / Facility	Amount (Rs. Crore)	Current Ratings	Rating Action	<a href="#">Complexity Indicator</a>
Long Term Facility – Fund Based – Term Loan	14.36 (Increased from Rs. 4.56 crores)	IVR BBB-/ Stable (IVR Triple B Minus with Stable Outlook)	Rating revised, CWDI** resolved and removed from Issuer Not Co-operating Category*)	Simple
Long term Bank Facility – Cash Credit	24.00 (Increased from Rs.22 crores)	IVR BBB-/ Stable (IVR Triple B Minus with Stable Outlook)	Rating revised, CWDI** resolved and removed from Issuer Not Co-operating Category*)	Simple
Short term Fund based Bank Facility – Letter of Credit	4.00	IVR A3 (IVR A Three)	Rating revised, CWDI** resolved and removed from Issuer Not Co-operating Category*)	Simple
<b>Total</b>	<b>42.36</b>	<b>(Rupees Forty-Two Crore and Thirty-Six Lakh only)</b>		

*\*Issuer did not cooperate; based on best available information*

*\*\*CWDI: Credit Watch with Developing Implications*

#### Details of Facilities are in Annexure 1

#### Detailed Rationale:

The revision of the ratings assigned to the bank facilities of LSPL factors in the overall improvement in the financial risk profile and its overall performance in H1FY23 which is expected to sustain in H2FY23 and beyond. It derives comfort from its extensive experienced promoters and established presence in the industry, long track record in pharmaceutical industry with diversified client base and wide marketing network, improved scale of operations and improved profit margin and debt protection metrics. However, the rating strengths are partially offset by working capital intensive operations, foreign exchange risk and presence in fragmented and competitive industry along with tender driven nature of business operations.



## Press Release

The ratings were placed under credit watch with developing implications owing to auditor qualification for delay in depositing undisputed statutory dues in FY20 audit report though none were outstanding at the year-end for a period of more than half yearly from the date they become payable. However, the audit report was clean pertaining to aforementioned observations in FY22 indicating that the Company is regular in paying its statutory dues within the timelines specified.

The rating was migrated to ISSUER NOT COOPEARTING category as Lotus Surgicals Private Limited (LSPL) had not submitted all the required information for surveillance under the stipulated timelines. Subsequently, LSPL has cooperated and provided the information leading to removal of the rating from ISSUER NOT COOPEARTING category.

### **Key Rating Sensitivities:**

#### **Upward Factors**

- Sustained and significant improvement in the scale of operations while improving profitability & debt protection metrics.

#### **Downward Factors**

- Any decline in scale of operations and/or profitability, leading significant deterioration of debt protection metrics.

### **Key Rating Drivers with detailed description**

#### **Key Rating Strengths:**

##### **Extensive experienced promoters and established presence in the industry:**

Mr. Mehernosh Daruwalla and Mrs. Coomi M Daruwalla are the promoters of the company and carry over two decades of average experience in the industry. Also, the company benefits from their experience as promoters are having long standing relationship with their customers and suppliers which reduces the counterparty default risk. LSPL successfully procures orders from a dealer network and from government organizations i.e., bids and also gets tender-based contracts, through its established presence in the market. The company also gets support from an experienced second line of management to support in day-to-day operations.



## Press Release

### **Long track record in pharmaceutical industry with diversified client base and wide marketing network:**

The company has an about one and half decade-long track record of operations in the pharmaceutical industry. LSPL have established strong relations with reputable customers in the medical industry. The company presently has one super stockiest who distributes its products across the country. It has dealers in foreign country namely Germany, United Kingdom, Indonesia, Uzbekistan, Philippines, Mozambique, and Bangladesh. LSPL has also won many states level tenders Tamil Nadu Medical Services Corp. Ltd., Gujarat Medical Services Corp Limited, West Bengal Central Medical Service Organization and others. The company has participated in many international health care conferences i.e. Arab Health in Dubai and Medica in Italy.

### **Improved scale of operations:**

The total operating income improved from Rs.84.26 crore in FY21 to Rs.116.16 crore in FY22 mainly because of the increase in top line and the expenses remaining at a stagnant rate. The proportion of expenses to total sales has also improved due to which there is a significant growth in the PAT margin. During H1FY23, the company has shown an increase in top line and in its PBT is more than double when compared with H1FY22. Hence, it is likely that the company will achieve the projections for FY23. The EBITDA margin has improved significantly from 16.27% in H1FY22 to 24.29% in H1FY23 owing to optimization of various fixed costs on the back of an increase in the scale of operations in that period.

### **Improved Profit Margins and debt protection metrics:**

LSPL reported a substantial increase in operating and net profit of INR 12.84 crore on account of an increase in export sales and a decline in imports of raw material in FY22 and beyond as these raw materials are now available locally at better and cheaper rates. The EBITDA and PAT margin improved from 13.62% and 8.88% in FY21 to 17.94% and 11.03% in FY22. The debt protection metrics of the company improved with interest coverage at 10.18x in FY22 vis-à-vis 4.29x in FY21 respectively and Total debt to GCA at 1.47x in FY22 vis-à-vis 9.83x in FY21 respectively.



## Press Release

### **B. Key Rating Weaknesses**

#### **Working Capital Intensive Operations:**

Pharma manufacturing operations are working capital intensive in nature marked by high inventory holding require procuring raw materials for manufacturing variety of products simultaneously. Further, LSPL's operations are also affected due to its high collection period, which further elongates the operating cycle. Consequently, the operating cycle of the company improved from 227 days in FY21 to 179 days in FY22. To fund its working capital requirements the company is largely dependent on bank borrowings and consequently it has a working capital limit utilization at ~70% in the past 12 months ending July 2022.

#### **Foreign Exchange risk:**

LSPL is vulnerable to unfavorable movements in foreign exchange given its consequential imports with no proper hedging policy in place; although some of the risk is reduced due to presence of in-house treasury team which tracks the foreign exchange fluctuation. The Company does not have any hedging policy and the amount is naturally hedged.

#### **Presence in fragmented and competitive industry along with tender driven nature of business operations:**

The company functions in an extremely competitive and fragmented medical equipment industry. LSPL observes high competition from both organized and unorganized players in the industry. This fragmented and extremely competitive industry derives from price competition. Hence, it affects the profit margins of the companies which are operating in the industry.

**Analytical Approach:** Standalone Approach

#### **Applicable Criteria:**

[Criteria of Rating Outlook](#)

[Rating Methodology for Manufacturing Companies](#)

[Financial Ratios & Interpretation \(Non-Financial Sector\)](#)



## Press Release

### Liquidity – Adequate

The liquidity position of the company remained adequate due to moderate cushion in gross accruals vis-à-vis repayment obligations. The Company maintains unencumbered cash and bank balances of INR 3.38 Crore as on March 31, 2022. Furthermore, the current ratio stood 1.86x as on March 31, 2022, and 1.51x as on March 31, 2021. The company's working capital utilisation also remains moderate at ~70% for the 12 months ended July 2022.

### About the Company:

Lotus Surgicals Private Limited (LSPL) incorporated in October 2005, located in Dehradun, Uttarakhand. The company is engaged in manufacturing of surgical and medical products primarily sutures, hernia mesh, skin staplers, handwash, handrub, hermosec clips, hermorrhoid stapler, and endoscopic linear cutter. The facility is WHOGMP, CE ISO certified.

### Financials Standalone

For the year ended/ As On	(Rs. crore)	
	31-03-2021 (Audited)	31-03-2022 (Audited)
Total Operating Income	84.26	116.16
EBITDA	11.44	20.84
PAT	2.62	12.84
Total Debt	25.71	25.67
Tangible Net-worth	31.46	46.30
<b>Ratios</b>		
EBITDA Margin (%)	13.58	17.94
PAT Margin (%)	3.11	11.03
Overall Gearing Ratio (x)	0.82	0.55

*\*Classification as per Infomerics Standards*

**Status of non-cooperation with previous CRA:** Brickwork Ratings in their press release dated November 10, 2022, have continued to classify Lotus Surgicals Private Limited as ISSUER NOT COOPERATING.

**Any other information:** Not Applicable



## Press Release

Rating History for last three years:

Sr. No	Name of Instrument/ Facilities	Current Ratings (Year 2022-23)				Rating History for the past years	
		Type	Amount (Rs. crore)	Rating	Date(s) & Rating assigned (Sept 15, 2022)	Date(s) & Rating assigned in 2021-22 (June 17, 2021)	Date(s) & Rating assigned in 2020-21
1.	Long Term Fund Based Facility – Term Loan	Long Term	14.36	IVR BBB-/ Stable	IVR BB+/ INC	IVR BBB-/ CWDI	--
2.	Long Term Fund Based Facility- Cash Credit	Long Term	22.00	IVR BBB-/ Stable	IVR BB+/ INC	IVR BBB-/ CWDI	--
3.	Short Term Fund based Bank Facility – Letter of Credit	Long Term	4.00	IVR A3	IVR A4+/ INC	IVR A3/ CWDI	--

### Name and Contact Details of the Rating Team:

Name: Shruti Sagothia

Tel.: (022) 6239 6023

[shruti.sagothia@infomerics.com](mailto:shruti.sagothia@infomerics.com)

Amit Bhuwania

Tel.: (022) 6239 6023

[abhuwania@infomerics.com](mailto:abhuwania@infomerics.com)

### About Infomerics:

Infomerics was founded in the year 1986 by a team of highly experienced and knowledgeable finance professionals. Subsequently, after obtaining Securities Exchange Board of India registration and RBI accreditation and the activities of the company are extended to External Credit Assessment Institution (ECAI).

Adhering to best International Practices and maintaining high degree of ethics, the team of knowledgeable analytical professionals deliver credible evaluation of rating.

Infomerics evaluates wide range of debt instruments which helps corporates open horizons to raise capital and provides investors enlightened investment opportunities. The transparent, robust and credible rating has gained the confidence of Investors and Banks.

Infomerics has a pan India presence with Head Office in Delhi, branches in major cities and representatives in several locations.

For more information visit [www.infomerics.com](http://www.infomerics.com)





## Press Release

Disclaimer: Infomerics ratings are based on information provided by the issuer on an 'as is where is' basis. Infomerics credit ratings are an opinion on the credit risk of the issue / issuer and not a recommendation to buy, hold or sell securities. Infomerics reserves the right to change, suspend or withdraw the credit ratings at any point in time. Infomerics ratings are opinions on financial statements based on information provided by the management and information obtained from sources believed by it to be accurate and reliable. The credit quality ratings are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. We, however, do not guarantee the accuracy, adequacy or completeness of any information, which we accepted and presumed to be free from misstatement, whether due to error or fraud. We are not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by us have paid a credit rating fee, based on the amount and type of bank facilities/instruments. In case of partnership/proprietary concerns/Association of Persons (AOPs), the rating assigned by Infomerics is based on the capital deployed by the partners/proprietor/ AOPs and the financial strength of the firm at present. The rating may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor/ AOPs in addition to the financial performance and other relevant factors.



## Press Release

### Annexure 1: Details of Facilities:

Name of Facility	Date of Issuance	Coupon Rate/ IRR	Maturity Date	Size of Facility (Rs. crore)	Rating Assigned/ Outlook
Term Loan	--	--	August 2024	2.36	IVR BBB-/ Stable
Term Loan (pending disbursement)	--	--	March 2028	12.00	IVR BBB-/ Stable
Cash Credit	--	--	--	24.00	IVR BBB-/ Stable
Letter of Credit	--	--	--	4.00	IVR A3

**Annexure 2: List of companies considered for consolidated analysis:** Not Applicable

### Annexure 3: Facility wise lender details:

<https://www.infomerics.com/admin/prfiles/Len-LSPL-dec22.pdf>

**Annexure 4: Detailed explanation of covenants of the rated instrument/facilities:** Not Applicable

**Note on complexity levels of the rated instrument:** Infomerics has classified instruments rated by it on the basis of complexity and a note thereon is available at <https://www.infomerics.com/>.